Mon, January 3, 2011
Fri, December 31, 2010
Thu, December 30, 2010
Wed, December 29, 2010
Tue, December 28, 2010
Mon, December 27, 2010
Fri, December 24, 2010
Thu, December 23, 2010
Wed, December 22, 2010
Tue, December 21, 2010
Mon, December 20, 2010
Fri, December 17, 2010
Thu, December 16, 2010
Wed, December 15, 2010
Tue, December 14, 2010
Mon, December 13, 2010
Sun, December 12, 2010
Fri, December 10, 2010
Thu, December 9, 2010
Wed, December 8, 2010
Tue, December 7, 2010
Mon, December 6, 2010
Fri, December 3, 2010
Thu, December 2, 2010

Inhibitex to Present at the 2010 Deutsche Bank BioFEST Conference on Tuesday, December 14th


//health-fitness.news-articles.net/content/2010/ .. biofest-conference-on-tuesday-december-14th.html
Published in Health and Fitness on Monday, December 13th 2010 at 15:20 GMT by Market Wire   Print publication without navigation


ATLANTA--([ BUSINESS WIRE ])--Inhibitex, Inc. (Nasdaq: INHX) today announced that Russell H. Plumb, president and chief executive officer, will present an overview of the company and its pipeline of differentiated antiviral compounds at the Deutsche Bank BioFEST Conference December 14, 2010 at 2:35 PM (ET). The conference is being held at The Four Seasons Hotel in Boston, MA. The presentation will be simultaneously webcast and can be accessed by visiting the Investors section of the Inhibitex website at[ www.inhibitex.com ]. Shortly following the live webcast, a replay will also be available on the Company website.

About Inhibitex

Inhibitex, Inc., a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Companya™s pipeline includes FV-100, which is in Phase II clinical development for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM® protein platform to Pfizer for the development of staphylococcal vaccines. For additional information about the Company, please visit [ www.inhibitex.com ].

Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex, Inc.


Publication Contributing Sources